1. 1 Cao H, Zhou Z, Wang L, et al. Screening of potential PFOS alternatives to decrease liver bioaccumulation: experimental and computational approaches. Environ Sci Technol 2019;53(5):2811-9. [
DOI:10.1021/acs.est.8b05564]
2. 2 World Health Organization. Who director-general's opening remarks at the media briefing on COVID-19-11 march 2020. 2020 [cited 2023; Available from: https://www.who.int/director-general/speeches/detail/who-director-general-sopening-remarks-at-the-media-briefing-on-covid-19e-11-march-2020.
3. 3 Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2021;27(3):451-7. [
DOI:10.1016/j.cmi.2020.10.021]
4. 4 Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020;185(4):599-606. [
DOI:10.1007/s11046-020-00462-9]
5. 5 Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect 2022;28(4):580-7. [
DOI:10.1016/j.cmi.2021.08.014]
6. 6 Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014;2014. [
DOI:10.1155/2014/562610]
7. 7 Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18(3):556-69. [
DOI:10.1128/CMR.18.3.556-569.2005]
8. 8 Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54(suppl_1):S23-S34. [
DOI:10.1093/cid/cir866]
9. 9 Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. The Lancet Microbe 2022. [
DOI:10.1016/S2666-5247(21)00237-8]
10. 10 Al Balushi A, Al Ajmi A, Al Sinani Q, et al. COVID-19-associated mucormycosis: an opportunistic fungal infection. A case series and review. Int J Infect Dis 2022;121:203-10. [
DOI:10.1016/j.ijid.2022.05.005]
11. 11 Ghazi BK, Rackimuthu S, Wara UU, et al. Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic. The American Journal of Tropical Medicine and Hygiene 2021;105(5):1144. [
DOI:10.4269/ajtmh.21-0608]
12. 12 Pasquier G. COVID-19-associated mucormycosis in India: why such an outbreak? Journal of Medical Mycology 2023:101393. [
DOI:10.1016/j.mycmed.2023.101393]
13. 13 Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186:289-98. [
DOI:10.1007/s11046-021-00528-2]
14. 14 Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12(9). [
DOI:10.7759/cureus.10726]
15. 15 Venkatesh D, Dandagi S, Chandrappa PR, Hema K. Mucormycosis in immunocompetent patient resulting in extensive maxillary sequestration. Journal of oral and maxillofacial pathology: JOMFP 2018;22(Suppl 1):S112. [
DOI:10.4103/jomfp.JOMFP_163_17]
16. 16 Sharma R, Kumar P, Rauf A, et al. Mucormycosis in the COVID-19 environment: a multifaceted complication. Frontiers in cellular and infection microbiology 2022;12:937481. [
DOI:10.3389/fcimb.2022.937481]
17. 17 Arjmand P, Bahrami M, Mohammadie ZE, et al. Mucormycosis in pre‐COVID‐19 and COVID‐19 era: A study of prevalence, risk factors and clinical features. Laryngoscope Investigative Otolaryngology 2022;7(5):1343-50. [
DOI:10.1002/lio2.899]
18. 18 Dogra S, Arora A, Aggarwal A, et al. Mucormycosis amid COVID-19 crisis: pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Frontiers in microbiology 2022;12:794176. [
DOI:10.3389/fmicb.2021.794176]
19. 19 Dam P, Cardoso MH, Mandal S, et al. Surge of mucormycosis during the COVID-19 pandemic. Travel Med Infect Dis 2023;52:102557. [
DOI:10.1016/j.tmaid.2023.102557]
20. 20 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021;15(4):102146. [
DOI:10.1016/j.dsx.2021.05.019]
21. 21 Talmi YP, Goldschmied-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngology-Head and Neck Surgery 2002;127(1):22-31. [
DOI:10.1067/mhn.2002.126587]
22. 22 Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022;32(4):NP11-NP6. [
DOI:10.1177/11206721211009450]
23. 23 Vaughan C, Bartolo A, Vallabh N, Leong SC. A meta‐analysis of survival factors in rhino‐orbital‐cerebral mucormycosis-has anything changed in the past 20 years? Clin Otolaryngol 2018;43(6):1454-64. [
DOI:10.1111/coa.13175]
24. 24 Sahoo NK, Kulkarni V, Bhandari AK, Kumar A. Mucormycosis of the frontal sinus: A rare case report and review. Annals of Maxillofacial Surgery 2017;7(1):120.
25. 25 Maliwan N, Reyes CV, Kippon JW. Osteomyelitis secondary to cutaneous mucormycosis: report of a case and a review of the literature. The American journal of dermatopathology 1984;6(5):479-82. [
DOI:10.1097/00000372-198410000-00011]
26. 26 Prabhakar A, Prabhakar N, Garg M, Kumar A. The Integral Role of Radiology in the Diagnosis and Management of COVID-19-Associated Mucormycosis Infections. The American Journal of Tropical Medicine and Hygiene 2022;106(4):1022. [
DOI:10.4269/ajtmh.21-1135]
27. 27 Agrawal A, Dixit Y, Yonati V, Nigam P, Kheti P. Imaging of COVID-19-associated rhino-orbital-cerebral mucormycosis: imaging analysis of 120 patients. The Egyptian Journal of Otolaryngology 2022;38(1):1-8. [
DOI:10.1186/s43163-022-00342-7]
28. 28 Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y. CT and MRI findings of invasive mucormycosis in the setting of COVID-19: experience from a single center in India. American Journal of Roentgenology 2021;217(6):1431-2. [
DOI:10.2214/AJR.21.26205]
29. 29 Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018;56(suppl_1):S93-S101. [
DOI:10.1093/mmy/myx101]
30. 30 Amanati A, Zekavat OR, Foroutan H, et al. Case reports of invasive mucormycosis associated neutropenic enterocolitis in leukemic children: diagnostic and treatment challenges and review of literature. BMC Infect Dis 2021;21:1-9. [
DOI:10.1186/s12879-021-06957-0]
31. 31 Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha) 2022;67(3):363-87. [
DOI:10.1007/s12223-021-00934-5]
32. 32 Arbune M, Arbune A-A, Nechifor A, Chiscop I, Sapira V. Diagnostic and Treatment Challenges of Emergent COVID-Associated-Mucormycosis: A Case Report and Review of the Literature. Antibiotics 2022;12(1):31. [
DOI:10.3390/antibiotics12010031]
33. 33 Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. Journal of Fungi 2019;5(1):26. [
DOI:10.3390/jof5010026]
34. 34 Kara I, Tasova Y, Uguz A, Sahin B. Mucormycosis‐associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2009;63(1):134-9. [
DOI:10.1111/j.1742-1241.2006.01145.x]
35. 35 Mirza H, Noori MAM, Akbar H, et al. Hypertension as an independent risk factor for in-patient mortality in hospitalized COVID-19 patients: a multicenter study. Cureus 2022;14(7). [
DOI:10.7759/cureus.26741]
36. 36 Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020;43(8):824-31. [
DOI:10.1038/s41440-020-0485-2]